GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Other Income (Expense)

China Isotope & Radiation (HKSE:01763) Other Income (Expense) : HK$135 Mil (TTM As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is China Isotope & Radiation Other Income (Expense)?

China Isotope & Radiation's other income expense for the China Isotope & Radiation's pretax income for the six months ended in Dec. 2023 was HK$123 Mil. Its other income expense for the trailing twelve months (TTM) ended in Dec. 2023 was HK$135 Mil.

China Isotope & Radiation Other Income (Expense) Historical Data

The historical data trend for China Isotope & Radiation's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Isotope & Radiation Other Income (Expense) Chart

China Isotope & Radiation Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Income (Expense)
Get a 7-Day Free Trial Premium Member Only 82.87 12.68 86.64 16.71 134.62

China Isotope & Radiation Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Income (Expense) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.98 1.48 15.29 11.41 123.21

China Isotope & Radiation Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$135 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Isotope & Radiation  (HKSE:01763) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

China Isotope & Radiation (HKSE:01763) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » China Isotope & Radiation Corp (HKSE:01763) » Definitions » Other Income (Expense)
Comparable Companies
HKSE:06669 HKSE:02160 HKSE:06922 HKSE:02190 HKSE:09996 HKSE:01696 HKSE:02407 HKSE:02500 HKSE:02235 HKSE:06118 ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
No. 66 Changwa Middle Street, Haidian District, Beijing, CHN, 100089
Website
https://www.china-isotope.com
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: Pharmaceuticals; Radioactive source products; Irradiation; Radiation therapy equipment and related services and Other businesses. Its Pharmaceutical segment is the key revenue driver, which manufactures and sells imaging diagnostic and therapeutic radiopharmaceuticals imaging, UBT diagnostic kits, and test analyzers, and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The Group's operations are carried out and majority of the Group's customers are located in the PRC.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Ubs Group Ag 2201 Interest of corporation controlled by you
Li Hongbo 2201 Interest of corporation controlled by you
Lianwen Ltd 2101 Beneficial owner
Invesco Advisers, Inc. 2102 Investment manager
The Bank Of New York Mellon Corporation 2201 Interest of corporation controlled by you
Invesco Hong Kong Limited 2102 Investment manager
Invesco Corporate Class Inc. 2106 Person having a security interest in shares
M&g Plc 2201 Interest of corporation controlled by you
Shanghai Industrial Holdings Limited 2201 Interest of corporation controlled by you
Shanghai Industrial Investment (holdings) Company Limited 2201 Interest of corporation controlled by you
Serenity Investment Master Fund Limited 2101 Beneficial owner
Serenity Capital Management, Ltd. 2102 Investment manager
Shanghai Pharmaceuticals Holding Co., Ltd. 2201 Interest of corporation controlled by you
S.i. Infrastructure Holdings Limited 2201 Interest of corporation controlled by you

China Isotope & Radiation (HKSE:01763) Headlines

No Headlines